887 A NOVEL MOUSE MODEL OF HEPATIC GLYCOGEN STORAGE DISEASE TYPE 3 IDENTIFIED USING A PHENOTYPE-DRIVEN ETHYL-NITROSOUREA (ENU) MUTAGENESIS SCREEN

2011 ◽  
Vol 54 ◽  
pp. S353
Author(s):  
P.M. Anstee ◽  
D. Concas ◽  
B. Wu ◽  
P. Potter ◽  
R. Cox ◽  
...  
Genes ◽  
2021 ◽  
Vol 12 (8) ◽  
pp. 1205
Author(s):  
Sarah Catharina Grünert ◽  
Luciana Hannibal ◽  
Ute Spiekerkoetter

Glycogen storage disease type VI (GSD VI) is an autosomal recessive disorder of glycogen metabolism due to mutations in the glycogen phosphorylase gene (PYGL), resulting in a deficiency of hepatic glycogen phosphorylase. We performed a systematic literature review in order to collect information on the clinical phenotypes and genotypes of all published GSD VI patients and to compare the data to those for GSD IX, a biochemically and clinically very similar disorder caused by a deficiency of phosphorylase kinase. A total of 63 genetically confirmed cases of GSD VI with clinical information were identified (median age: 5.3 years). The age at presentation ranged from 5 weeks to 38 years, with a median of 1.8 years. The main presenting symptoms were hepatomegaly and poor growth, while the most common laboratory findings at initial presentation comprised elevated activity of liver transaminases, hypertriglyceridemia, fasting hypoglycemia and postprandial hyperlactatemia. Liver biopsies (n = 37) showed an increased glycogen content in 89.2%, liver fibrosis in 32.4% and early liver cirrhosis in 10.8% of cases, respectively. No patient received a liver transplant, and one successful pregnancy was reported. Our review demonstrates that GSD VI is a disorder with broad clinical heterogeneity and a small number of patients with a severe phenotype and liver cirrhosis. Neither clinical nor laboratory findings allow for a differentiation between GSD VI and GSD IX. Early biochemical markers of disease severity or clear genotype phenotype correlations are missing. Given the overall benign and unspecific phenotype and the need for enzymatic or genetic analyses for confirmation of the diagnosis, GSD VI is likely underdiagnosed. With new treatment approaches in sight, early, pre-symptomatic diagnosis, especially with respect to hepatic cirrhosis, will become even more important.


Life Sciences ◽  
2002 ◽  
Vol 71 (11) ◽  
pp. 1293-1301 ◽  
Author(s):  
A. Zingone ◽  
J. Seidel ◽  
L. Aloj ◽  
C. Caraco ◽  
J.J. Vaquero ◽  
...  

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii80-iii80
Author(s):  
Monika Gjorgjieva ◽  
Julie Clar ◽  
Margaux Raffin ◽  
Adeline Duchampt ◽  
Anne Stefanutti ◽  
...  

2016 ◽  
Vol 117 ◽  
pp. S69
Author(s):  
Zakir Lazoğlu ◽  
Uğur Aksu ◽  
Kamuran Kalkan ◽  
Oktay Gulcu ◽  
Selim Topcu

2014 ◽  
Vol 34 (5) ◽  
pp. 390-395 ◽  
Author(s):  
Sulman Basit ◽  
Omhani Malibari ◽  
Alia Mahmood Al Balwi ◽  
Firoz Abdusamad ◽  
Feras Abu Ismail

2019 ◽  
Vol 29 (2) ◽  
pp. 286-294 ◽  
Author(s):  
Zollie A Yavarow ◽  
Hye-Ri Kang ◽  
Lauren R Waskowicz ◽  
Boon-Huat Bay ◽  
Sarah P Young ◽  
...  

Abstract Glycogen storage disease type Ia (GSD Ia) is caused by autosomal mutations in glucose-6-phosphatase α catalytic subunit (G6PC) and can present with severe hypoglycemia, lactic acidosis and hypertriglyceridemia. In both children and adults with GSD Ia, there is over-accumulation of hepatic glycogen and triglycerides that can lead to steatohepatitis and a risk for hepatocellular adenoma or carcinoma. Here, we examined the effects of the commonly used peroxisomal proliferated activated receptor α agonist, fenofibrate, on liver and kidney autophagy and lipid metabolism in 5-day-old G6pc −/− mice serving as a model of neonatal GSD Ia. Five-day administration of fenofibrate decreased the elevated hepatic and renal triglyceride and hepatic glycogen levels found in control G6pc −/− mice. Fenofibrate also induced autophagy and promoted β-oxidation of fatty acids and stimulated gene expression of acyl-CoA dehydrogenases in the liver. These findings show that fenofibrate can rapidly decrease hepatic glycogen and triglyceride levels and renal triglyceride levels in neonatal G6pc −/− mice. Moreover, since fenofibrate is an FDA-approved drug that has an excellent safety profile, our findings suggest that fenofibrate could be a potential pharmacological therapy for GSD Ia in neonatal and pediatric patients as well as for adults. These findings may also apply to non-alcoholic fatty liver disease, which shares similar pathological and metabolic changes with GSD Ia.


2018 ◽  
Vol 19 (4) ◽  
pp. 203-210 ◽  
Author(s):  
Ferdos Nazari ◽  
Farnaz Sinaei ◽  
Yalda Nilipour ◽  
François Petit ◽  
Shahram Oveisgharan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document